Russell Investments Group
LGND icon

Russell Investments Group’s Ligand Pharmaceuticals LGND Stock Holding History

Russell Investments Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.2M Sell
121,151
-17,313
-13% -$3.43M 0.03% 577
2025
Q4 		$26.2M Buy
138,464
+2,334
+2% +$448K 0.03% 534
2025
Q3 		$24.1M Sell
136,130
-9,403
-6% -$1.4M 0.03% 555
2025
Q2 		$16.5M Buy
145,533
+10,168
+8% +$1.09M 0.02% 647
2025
Q1 		$14.2M Buy
135,365
+39,765
+42% +$4.5M 0.02% 690
2024
Q4 		$10.2M Sell
95,600
-20,654
-18% -$2.33M 0.01% 807
2024
Q3 		$11.6M Buy
116,254
+24,790
+27% +$2.5M 0.02% 774
2024
Q2 		$7.71M Buy
91,464
+18,303
+25% +$1.46M 0.01% 948
2024
Q1 		$5.35M Buy
73,161
+44,499
+155% +$3.28M 0.01% 1137
2023
Q4 		$2.05M Buy
28,662
+11,345
+66% +$670K ﹤0.01% 1603
2023
Q3 		$1.04M Sell
17,317
-30,777
-64% -$2.03M ﹤0.01% 1906
2023
Q2 		$3.47M Sell
48,094
-8,351
-15% -$627K 0.01% 1248
2023
Q1 		$4.15M Buy
56,445
+18,568
+49% +$1.32M 0.01% 1188
2022
Q4 		$2.53M Buy
37,877
+23,437
+162% +$1.52M 0.01% 1443
2022
Q3 		$775K Hold
14,440
– – ﹤0.01% 2051
2022
Q2 		$803K Hold
14,440
– – ﹤0.01% 2056
2022
Q1 		$1.01M Sell
14,440
-12,431
-46% -$902K ﹤0.01% 1957
2021
Q4 		$2.59M Sell
26,871
-2,425
-8% -$224K ﹤0.01% 1660
2021
Q3 		$2.54M Sell
29,296
-3,088
-10% -$239K ﹤0.01% 1690
2021
Q2 		$2.65M Sell
32,384
-12,377
-28% -$1.03M ﹤0.01% 1747
2021
Q1 		$4.25M Sell
44,761
-179,189
-80% -$16.9M 0.01% 1444
2020
Q4 		$13.9M Sell
223,950
-41,074
-15% -$2.34M 0.03% 670
2020
Q3 		$15.8M Buy
265,024
+31,103
+13% +$2.12M 0.03% 569
2020
Q2 		$16.3M Sell
233,921
-20,281
-8% -$1.29M 0.04% 535
2020
Q1 		$11.5M Buy
254,202
+29,090
+13% +$1.65M 0.03% 596
2019
Q4 		$14.6M Buy
225,112
+8,819
+4% +$589K 0.03% 677
2019
Q3 		$13.4M Sell
216,293
-28,631
-12% -$1.8M 0.03% 714
2019
Q2 		$17.4M Buy
244,924
+8,275
+3% +$609K 0.03% 617
2019
Q1 		$18.6M Sell
236,649
-48,318
-17% -$3.66M 0.03% 605
2018
Q4 		$24.1M Buy
284,967
+37,805
+15% +$4.03M 0.05% 411
2018
Q3 		$42.3M Sell
247,162
-63,150
-20% -$9.52M 0.08% 271
2018
Q2 		$40.1M Sell
310,312
-111,925
-27% -$12.5M 0.08% 261
2018
Q1 		$43.5M Sell
422,237
-111,950
-21% -$11.1M 0.07% 319
2017
Q4 		$46.2M Sell
534,187
-36,077
-6% -$3.13M 0.08% 308
2017
Q3 		$48.4M Sell
570,264
-26,797
-4% -$2.12M 0.08% 289
2017
Q2 		$45.2M Buy
597,061
+164,935
+38% +$11.5M 0.08% 307
2017
Q1 		$28.5M Sell
432,126
-15,618
-3% -$1.03M 0.05% 435
2016
Q4 		$28.4M Buy
+447,744
New +$28.3M 0.06% 423

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Russell Investments Group's LGND Position: Q1 2026 in Review

Russell Investments Group reduced its Ligand Pharmaceuticals (LGND) stake by 13% in Q1 2026, selling an estimated $3.43M and leaving 121,151 shares worth $24.2M. The position accounts for 0.03% of the portfolio, ranked #577.

Russell Investments Group first reported a position in LGND in Q4 2016 and has held it in 38 quarters since. The position peaked at $48.4M in Q3 2017. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Russell Investments Group held 121,151 shares of Ligand Pharmaceuticals worth $24.2M as of Q1 2026.
  • Russell Investments Group sold 17,313 Ligand Pharmaceuticals shares in Q1 2026, an estimated $3.43M.
  • Ligand Pharmaceuticals made up 0.03% of Russell Investments Group's portfolio in Q1 2026, its #577 holding.
  • Russell Investments Group first reported a position in Ligand Pharmaceuticals in Q4 2016 and has held it in 38 quarters since.
  • Russell Investments Group's Ligand Pharmaceuticals position peaked at $48.4M in Q3 2017.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.